{
  "docId": "019de077-2202-715b-adea-57c1f9ae9ce5",
  "docSlug": "719db50244a96da2bbf79cc8f7d91684",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 26 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 26,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide outlines two parallel study arms involving Imdusiran, VTP-300, NA, and Nivolumab.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-2202-715b-adea-57c1f9ae9ce5/15",
  "deckHref": "/decks/019de077-2202-715b-adea-57c1f9ae9ce5",
  "deckJsonHref": "/decks/019de077-2202-715b-adea-57c1f9ae9ce5.json",
  "deckAnchorHref": "/decks/019de077-2202-715b-adea-57c1f9ae9ce5#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.7,
        "x": 0.28,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Clinical trial timeline showing two arms with randomization at week 24",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79d42bc3-76aa-4845-a691-424beffda1ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.04,
        "y": 0.53
      },
      "kind": "paragraph",
      "text": "POC Phase 2a clinical trial evaluating imdusiran in combination with Barinthus Bio’s immunotherapeutic, VTP-300, and NA with or without low dose nivolumab",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e6ea385-9b28-4371-b294-4a964c22a0dd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.65,
        "x": 0.31,
        "y": 0.56
      },
      "kind": "paragraph",
      "text": "Primary objective: evaluate safety and reactogenicity of imdusiran followed by VTP-300 or placebo. At Week 48 all participants who are eligible to discontinue NA therapy will be followed for an additional 48 weeks. Results presented at EASL Congress 2024 showed that imdusiran followed by VTP-300 was generally safe and well-tolerated and led to maintenance of lower HBsAg levels during the post-treatment follow-up period. Clinical trial expanded to include an additional arm with nivolumab (Opdivo®) with preliminary data expected in 2H 2024. Full rights retained by the Companies of their respective product candidates and all costs split equally",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e89d11dd-e92a-49d6-8c6d-f07166ee8055",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "title",
      "text": "IM-PROVE II: Phase 2a POC Clinical Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a1ae0d3-a65e-487e-8dca-1a56e66c003c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "73a768d5-5851-4548-8b81-e73821eddb28",
      "evidence": "Visual representation of clinical trial phases over time",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 17,
      "from": 13,
      "beatId": "a03442fb-e554-4013-a27a-a70f868887ac",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document showcases positive clinical trial results for Imdusiran and AB-101.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}